ReviewFrontiers in medicine2020
Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Understanding "Alert Fatigue" in Primary Care: Qualitative Systematic Review of General Practitioners Attitudes and Experiences of Clinical Alerts, Prompts, and Reminders.Journal of medical Internet research · 2025Pooled it
- A systematic review of the early dialogue frameworks used within health technology assessment and their actual adoption from HTA agencies.Frontiers in public health · 2022Pooled it
- Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada.Journal of market access & health policy · 2026Article
- The registration status of maternal, newborn, and child health medical products: evidence from 9 countries.Journal of pharmaceutical policy and practice · 2026Article
- Identification and Description of Regulatory and Health Technology Assessment Agencies' Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific.Therapeutic innovation & regulatory science · 2025Article
- The Art of Bridge Building: A Look at the European-Level Cooperation in HTA (EU-HTA).Journal of market access & health policy · 2025Article
- Article
- Methods for the health technology assessment of complex interventions: A scoping review.PloS one · 2025Article
- The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.Drug safety · 2024Article
- Ensuring safety and efficacy in combination products: regulatory challenges and best practices.Frontiers in medical technology · 2024Review
- Methodological guidelines and publications of benefit-risk assessment for health technology assessment: a scoping review protocol.BMJ open · 2023Article
- Knowledge management tools and mechanisms for evidence-informed decision-making in the WHO European Region: a scoping review.Health research policy and systems · 2023Article
- Article
- Synergy between health technology assessments and clinical guidelines for multiple sclerosis.Clinical and translational science · 2023Article
- Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.International journal of technology assessment in health care · 2023Article
- Access to medicines for rare diseases: A European regulatory roadmap for academia.Frontiers in pharmacology · 2023Article
- Real-world evidence for regulatory decision-making: updated guidance from around the world.Frontiers in medicine · 2023Review
- Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.Current oncology (Toronto, Ont.) · 2022Review
- Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast].International journal of general medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need to optimize drug development and facilitate faster access for patients has ignited discussions around the importance of improving interactions between health technology assessment (HTA) bodies and regulatory agencies. In this study, we conducted a systematic review to examine processes, progress, outcomes, and challenges of harmonization/interaction initiatives between HTA bodies and regulatory agencies. MEDLINE, EMBASE, and the International Pharmaceutical Abstracts database were searched up to 21 October 2019. Searches for gray literature (working papers, commissioned reports, policy documents, etc.) were performed via Google scholar and several institutional websites. An online cross-sectional survey was also conducted among HTA (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.